🫁 This Friday is World Lung Cancer Day.
At Flomics, we’re developing RNA-based liquid biopsy tools for early, non-invasive detection.
Every dataset matters. Every life matters.
🎗️ To patients, families & researchers: we see you, we work for you.
#WorldLungCancerDay #EarlyDetection #Flomics

No endless waiting ⏳
No invasive procedures 💉
Just fast, accurate, and early answers ⚡

Our goal: detect cancer early through a simple blood test — powered by RNA🩸🧬

Behind every breakthrough is a dedicated team 🧬💻🧪

#LiquidBiopsy #RNA #CancerDetection #Bioinformatics #PrecisionMedicine #TeamScience

Thanks @biorxiv-bioinfo.bsky.social for hosting our new study!
We’ve unpacked the findings in detail — here’s the full thread → bsky.app/profile/flom...

Together, step by step, we’re making great strides — the best is yet to come!🚀💪

#LiquidBiopsy #CfRNA #RNASeq #Transcriptomics #Biomarkers #Bioinformatics #PrecisionMedicine #Preprint #CancerDiagnostics #Flomics #MethodsMatter #Reproducibility #Genomics #Diagnostics

And a huge thanks to our incredible team:

@julienlag.bsky.social, @ctuni.bsky.social, @fokkerplanck.bsky.social, @asoleee.bsky.social, Pablo Monteagudo, Elena Rusu, Lluc Cabus, Lucila González, Laura Sánchez, Beatriz Nieto & Phil Sanders who made this possible!

🙏 Thanks to @upf.edu, @crg.eu, @idibaps.bsky.social, @cienciagob.bsky.social, @leitat.bsky.social and other collaborators for their invaluable support and contribution!

We believe this resource will be very useful to researchers, clinicians, and companies in the liquid biopsy space. We welcome constructive feedback and discussion!

And now for a not-so-humble brag…
We were thrilled when the analysis revealed our own in-house Flomics libraries, using a rigorous double-DNase digestion protocol, ranked as the highest-quality dataset among all whole-cfRNA-Seq methods! 🎉💪

But we’re not just here to point out problems!
Our work provides a data-driven benchmark of what works, and a roadmap for more robust studies.

Beware of confounders!
We highlight how technical factors are often mixed with patient phenotype, making true, generalizable biomarker discovery a huge challenge.

Protocols are not created equal. We show how different workflows give you vastly different pictures of the transcriptome.

This technical noise is loud!
The variation we found is greater than the biological variation across 29 different human tissues. Let that sink in.

It’s the method, not the biology.
We found that inter-lab batch effects, genomic DNA contamination, and library diversity explain the main differences between samples.

We had a hunch, so we conducted a massive cross-study analysis of >2,300 samples from 15 studies, plus libraries generated in-house at Flomics. We used a uniform bioinformatics pipeline to see what was really going on.

Results were… illuminating.

Systematic cross-study assessment of RNA-Seq experimental workflows for plasma cell-free transcriptome profiling Plasma cell-free RNA (cfRNA) is a promising source of non-invasive biomarkers, but its clinical translation is hindered by technical challenges and a lack of protocol standardization, which compromise...

Fresh insights from the Flomics team! 🧬💻

Our new preprint is out:
“Systematic cross-study assessment of RNA-Seq workflows for plasma cfRNA profiling”
Is cfRNA the wild west of protocols? We investigated.

📄 Read it: www.biorxiv.org/cgi/content/...

But we’re not just here to point out problems! Our work provides a data-driven benchmark of what works, and a roadmap for more robust studies.

Beware of confounders!
We highlight how technical factors are often mixed with patient phenotype, making true, generalizable biomarker discovery a huge challenge.

Protocols are not created equal.
We show how different workflows give you vastly different pictures of the transcriptome.

This technical noise is loud!
The variation we found is greater than the biological variation across 29 different human tissues. Let that sink in.

It’s the method, not the biology.
We found that inter-lab batch effects, genomic DNA contamination, and library diversity explain the main differences between samples.

Something exciting is on the way…⌛
We're bringing RNA-based diagnostics one step closer to the clinic.
Stay tuned — the news drops very soon. 🚀
#LiquidBiopsy #Transcriptomics #Biomarkers #OpenScience

👋 Hi Bluesky! We’re Flomics, a biotech company focused on liquid biopsy & transcriptomics.
Passionate about robust science, reproducibility & biomarker discovery.
Excited to join the community — stay tuned for our first big announcement! 🚀
#LiquidBiopsy #Genomics #OpenScience